DOCSLIB.ORG

Platelets and Their Beneficial and Detrimental Roles in Immunity JOHN W

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Platelets and Their Beneficial and Detrimental Roles in Immunity JOHN W Platelets and their Beneficial and Detrimental Roles in Immunity JOHN W. SEMPLE PROFESSOR OF TRANSFUSION MEDICINE, LUND UNIVERSITY Talk Outline: 1.Platelets: general aspects 2.Platelets and immunity 3.Conclusions Platelets: general aspects Platelet Haemostatic Function: Resting Platelets Activated Platelets Advances in Platelet Biology 1998, Henn, platelet CD154 expression 1979, Ashi, others, platelet-bacterial interactions 2003, Elzy, platelets mediate adaptive immunity. 1971 Vane 1874 Osler Shows aspirin prevents Platelets are real 1918 Glanzmann platelet aggregation cells Describes “weak” 2008, Weyrich, others, platelet disease platelets differentiate and divide 1800 1900 2000 1842 Donne 1962 Born First describes platelet isolation 2004, platelets Semple, others, platelet TLR expression 1882 Bizzozero 1974 Nurden & Caen Names platelets GPIIb/IIIa associated with & popularizes platelet aggregation clotting function 1985 Stenberg 2005/6, 1906 Wright Platelet-derived P-selectin supports Kubes, Semple, others, Discovers that Megakaryocytes leukocyte adhesion platelet TLR is functional are the precursors of platelets Courtesy of AS Weyrich, adapted. Platelets are Immune cells. Kapur R et al. J Immunol, 2015, 194: 5579–5587 Why do platelets have immune properties? Evolutionary links of platelet immunity: Hemocytes Thrombocytes Platelets •Phagocytes (Mac.-like). •Aggregate and gel/clot plasma. •Aggregate and clot plasma. •Anti-bacterial peptides. •Phagocytic. •Phagocytic. •Express TLR/innate receptors. •Express TLR/innate receptors. •Express TLR/innate receptors. •Can aggregate and clot •Anti-bacterial peptides. •Anti-bacterial peptides. hemolymph at sites of injury. Invertebrates Vertebrates Mammals Levin J In: Platelets, 4th Ed., 2019 Evolutionary links of platelet immunity: Hemocytes Thrombocytes Platelets •Phagocytes (Mac.-like). •Aggregate and gel/clot plasma. •Aggregate and clot plasma. •Anti-bacterial peptides. •Phagocytic. •Phagocytic. •Express TLR/innate receptors. •Express TLR/innate receptors. •Express TLR/innate receptors. •Can aggregate and clot •Anti-bacterial peptides. •Anti-bacterial peptides. hemolymph at sites of injury. Invertebrates Vertebrates Mammals Levin J In: Platelets, 4th Ed., 2019 Evolutionary links of platelet immunity: Hemocytes Thrombocytes Platelets •Phagocytes (Mac.-like). •Aggregate and gel/clot plasma. •Aggregate and clot plasma. •Anti-bacterial peptides. •Phagocytic. •Phagocytic. •Express TLR/innate receptors. •Express TLR/innate receptors. •Express TLR/innate receptors. •Can aggregate and clot •Anti-bacterial peptides. •Anti-bacterial peptides. hemolymph at sites of injury. Invertebrates Vertebrates Mammals Levin J In: Platelets, 4th Ed., 2019 Evolutionary links of platelet immunity: Hemocytes Thrombocytes Platelets •Phagocytes (Mac.-like). •Aggregate and gel/clot plasma. •Aggregate and clot plasma. •Anti-bacterial peptides. •Phagocytic. •Phagocytic. •Express TLR/innate receptors. •Express TLR/innate receptors. •Express TLR/innate receptors. •Can aggregate and clot •Anti-bacterial peptides. •Anti-bacterial peptides. hemolymph at sites of injury. Invertebrates Vertebrates Mammals Levin J In: Platelets, 4th Ed., 2019 Is it possible?: Oyster Hemocytes Human Bronchial Macrophages (Rebelo MdF et al. PLoS ONE 8(2): e57384. doi:10.1371) (Creative Commons) Macrophage •Host Defense. •hemostasis (TF etc.) Hemocyte •Host Defense •Hemostasis Platelet Complexity •Hemostasis requires •Host defense (TLR etc.) specialization Platelets and Immunity Immune Regulation Direct Effects Anti-infectious P-selectin adhesion Effects Chemokine Recep. TLR 1-9 Allo. vs Autol. HLA Thrombocidins (Transplant./Transfusion) Β-defensins CD40/CD40L Neutrophil activation (T cell activation, Dendritic cell diff.) Cancer Autoimmunity Immune Resistance Effects Effects CD40/CD40L HLA transfer. Microparticles Microparticles IL1/IL8 Cytokines Platelet mass NK resistance Interaction between inflammation, hemostasis and the plaque: Wagner DD. Arterioscler Thromb Vasc Biol. 2005;25:1321-4. Adherence and Vascular smooth Inflammatory Adherence and Foam-cell aggregation of muscle cell cell activation entry of white blood cells formation platelets migration TRIM (Transfusion related immunomodulation): In 1999, Blajchman coined the term “Transfusion- Related Immunomodulation” (TRIM) in an attempt to unify the immunosuppressive effects of blood transfusions. Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999;39:665-70. Resting Allogeneic Platelets turn off CD8+ T cells. Resting allogeneic platelets mediate TRIM: 108 BALB/c or SCID (H-2d) platelets weekly BALB/c or SCID skin graft CBA (H-2k) t Blood Collection Time to graft Pre- (anti-donor Abs) rejection. bleed Aslam et al. Transfusion. 48:1778-1786, 2008 Resting allogeneic platelets mediate TRIM: 108 BALB/c or SCID (H-2d) platelets weekly BALB/c or SCID skin graft CBA (H-2k) t Blood Collection Time to graft Pre- (anti-donor Abs) rejection. bleed Aslam et al. Transfusion. 48:1778-1786, 2008 Resting allogeneic platelets mediate TRIM: Non-transfused CBA Recipient (13 day post-transplant of Different BALB/c skin) allo-platelet transfusions CTL Non- transfused Skin MHC Rejection Platelet-transfused CBA Recipient (30 day post- transplant of BALB/c skin) Transfused allogeneic platelets Skin Rejection MHC Inhibited Aslam et al. Transfusion. 48:1778-1786, 2008 Upon Storage, Platelet bags accumulate Pro- and Anti- inflammatory agents: Cytokines (e.g. IL1, TGF, PF4) Serotonin HLA molecules Residual Leukocytes Oxidized Lipids Chemokines (e.g. CXCl1-7) CD40L Human soluble MHC class I from platelets and immunomodulation: Ghio et al Blood 93:1770, 1999 Puppo et al Int Immunol 12:195, 1999 Fournel et al J Immunol 164:6100, 2000 Spaggiari et al Blood 99:1706, 2002 Ghio et al Transfusion 48:1591, 2008 Using in vitro assays, soluble MHC class I molecules can induce immunosuppression via the induction of Fas-dependent apoptosis in CD8+ T cells and Natural Killer cells. Platelets are Immune cells. Kapur R et al. J Immunol, 2015, 194: 5579–5587 Activated platelets are more immunoregulatory than resting platelets: TREM-1 MHC Class I TLR 1-9 MHC Class I (denatured) (denatured) TLR 1,2,4-6 Resting Activated Platelet Platelet MHC Class I CD40L (Intact) CD40 T cell B cell and T cell Suppression Activation/Suppression Platelets are Immune cells. Kapur R et al. J Immunol, 2015, 194: 5579–5587 Activated Platelets release many immunomodulatory molecules: Cytokines IL-1β MHC class I (Inflammation) (CD8+ T cell interactions) TGF-β (immunosuppression) CD40L/CD40 Chemokines CXCL, CCL Activated (Cell recruitment) Platelet Lipid Mediators, 12-HETE (Inflammation) Thrombocidins (anti-microbial) β-Defensins PF4 (anti-microbial) Serotonin, 5-HT (Inflammation) November 2011 | Volume 7 | Issue 11 | e1002355 Kapur R et al. J Immunol, 2015, 194: 5579–5587 T cell activation is regulated by signals derived from the TCR/CD3/CD4 complex and the CD40L (CD154) and CD28/CTLA-4 co-stimulatory molecules: CD4+ T Cell Co-stimulatory signals Antigen specific TCR signals (- ) / [+] lck CD3 γ δ ε ζ ζ η η Cα Cβ α,β CD28/ Vα Vβ TCR CTLA-4 CD40L Peptide antigen CD40 CD4 MHC class II signal CD80 (B7.1)/ [+] CD86 (B7.2) Antigen Presenting Cell (APC) Platelet CD40L (CD154) expression and function in ITP: Blood. 2005;105:215-218 Patients with active disease Autoreactive B cell CD154 CD40 Activated Plt CD154 expression Ig GPIIbIIIa Anti-GPIIbIIa autoantibodies Kapur R et al. J Immunol, 2015, 194: 5579–5587 Activated platelets have the ability to stimulate CD8+ T cells: Mol Cell Proteomics 13:3308–3319, 2014. Platelets contain all the machinery necessary for cross presentation to CD8+ T cells: DenaturedDenatured MHC Class I + (plasma) Alpha granule α-granule PDI Platelets can cross present antigens to CD8+ T cells: Target Lysis (platelets and MK) CD8+ T cell CD40/80/86 CD154 Activated Plt MHC I expression TcR MHC Class I plasmodium peptide Activated murine MHC class I+ platelets present plasmodium peptides to CD8+ T cells and can act as a Ag delivery vehicles to protect against P. berghei induced fatal experimental cerebral malaria (ECM). PbA-OVA: Plasmodium berghei ANKA-OVA Can megakaryocytes (MK) cross-present antigen? Exogenous Protein Antigen Internalization APC CD8+ T cell Loading peptide onto MHC class I Presentation to CD8+ T cells MKs move OVA into endosomes, lysosomes and alpha granules. MKs load the OVA immunogenic peptide onto MHC Class I molecules Zufferey A et al. 1:1773-1785, 2017 While MKs process and present OVA, they are capable of transferring the MHC-OVA complexes to platelets. Malarial peptides Ovalbumin peptides Endogenous GPIIIa peptides Zufferey A et al. 1:1773-1785, 2017 Platelets MK MHC class I Proteasome Endosomes TAP Self Platelet Protein CD8+ Foreign Protein Lysosomes T cell Ag Zufferey A et al. Blood Adv. 1(20):1773-1785, 2017 Conclusions: Resting platelets tend to be immunosuppressive for adaptive immunity whereas activated platelets have the ability to turn on adaptive immune responses. Platelets express a variety of pro- and anti-inflammatory molecules that link them with autoimmune (ITP) and alloimmune (transfusions) regulation. Although platelets and MK are considered innocent bystanders and are the target of immune attack, evidence suggests that they can significantly influence Immune effector systems. Taken together, it appears that platelets and megakaryocytes have a critical role to play as infectious circulating sentinels and immunomodulators. Thank You Questions?.
Load more

Recommended publications
  • M.Tech. BT ( R14 Regulations)
    M.Tech. BT ( R14 Regulations) CMR COLLEGE OF ENGINEERING & TECHNOLOGY (An Autonomous Institution) ACADEMIC REGULATIONS FOR M. TECH. (REGULAR) DEGREE COURSE Applicable for the students of M. Tech. (Regular) Course from the Academic Year 2014-15 and onwards The M. Tech. degree shall be conferred on candidates who are admitted to the program and who fulfil all the requirements for the award of the degree. 1.0 Eligibility for Admissions Admission to the above program shall be made subject to eligibility, qualification and specialization as prescribed by the State Government from time to time. 2.0 Award of M. Tech. degree 2.1 A student shall be declared eligible for the award of the M. Tech. Degree, if he pursues a course of study in not less than two and not more than four academic years. 2.2 A student, who fails to fulfill all the academic requirements for the award of the degree within four academic years from the year of his admission, shall forfeit his seat in M. Tech. course. 2.3 The student shall register for all 88 credits and secure all the 88 credits. 2.4 The minimum instruction days in each semester are 90. 2.5 The medium of instruction and examination shall be English. 3.0 A. Courses of Study The following specializations are offered at present for the M. Tech. course of study. 1. Bio-Technology 2. Embedded Systems 3. Power Electronics 4. Structural Engineering 5. Computer Science & Engineering 6. Machine Design and any other course as approved by the College/ University/AICTE from time to time.
    [Show full text]
  • Defining Natural Antibodies
    PERSPECTIVE published: 26 July 2017 doi: 10.3389/fimmu.2017.00872 Defining Natural Antibodies Nichol E. Holodick1*, Nely Rodríguez-Zhurbenko2 and Ana María Hernández2* 1 Department of Biomedical Sciences, Center for Immunobiology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States, 2 Natural Antibodies Group, Tumor Immunology Division, Center of Molecular Immunology, Havana, Cuba The traditional definition of natural antibodies (NAbs) states that these antibodies are present prior to the body encountering cognate antigen, providing a first line of defense against infection thereby, allowing time for a specific antibody response to be mounted. The literature has a seemingly common definition of NAbs; however, as our knowledge of antibodies and B cells is refined, re-evaluation of the common definition of NAbs may be required. Defining NAbs becomes important as the function of NAb production is used to define B cell subsets (1) and as these important molecules are shown to play numerous roles in the immune system (Figure 1). Herein, we aim to briefly summarize our current knowledge of NAbs in the context of initiating a discussion within the field of how such an important and multifaceted group of molecules should be defined. Edited by: Keywords: natural antibody, antibodies, natural antibody repertoire, B-1 cells, B cell subsets, B cells Harry W. Schroeder, University of Alabama at Birmingham, United States NATURAL ANTIBODY (NAb) PRODUCING CELLS Reviewed by: Andre M. Vale, Both murine and human NAbs have been discussed in detail since the late 1960s (2, 3); however, Federal University of Rio cells producing NAbs were not identified until 1983 in the murine system (4, 5).
    [Show full text]
  • Important Information for Female Platelet Donors
    Important Information for Female Platelet Donors We are grateful for the support you provide our community blood program and especially appreciate your willingness to help save lives as a volunteer platelet donor. We also take our responsibility to provide a safe and adequate blood supply very seriously and need to share the following information regarding a change to our donor eligibility criteria for female platelet donors. We recently began performing a Human Leukocyte Antigen (HLA) antibody test on each of our current female platelet donors who have ever been pregnant. In addition, we modified our Medical History Questionnaire to ask donors whether they have been pregnant since their last donation. Platelet donors who respond yes to that question will be screened for HLA antibodies. Platelet donors will also be retested after every subsequent pregnancy. These adjustments are being made as part of our effort to reduce occurrences of Transfusion-Related Acute Lung Injury (TRALI). TRALI is a rare but serious complication of blood transfusions most commonly thought to be caused by a reaction to HLA antibodies present in the donor’s plasma. When transfused, these antibodies can sometimes cause plasma to leak into the patient’s lungs, creating fluid accumulation — a condition referred to as acute pulmonary edema. Female donors who have been pregnant are more likely than others to have these HLA antibodies in their plasma. Once the antibodies develop, they are present forever. The antibodies could be harmful if transfused into certain patients. The antibodies are present in plasma — and platelet donations contain a high volume of plasma, so our current efforts are directed at screening blood samples from female platelet donors to test for the HLA antibody.
    [Show full text]
  • Instant Notes: Immunology, Second Edition
    Immunology Second Edition The INSTANT NOTES series Series Editor: B.D. Hames School of Biochemistry and Molecular Biology, University of Leeds, Leeds, UK Animal Biology 2nd edition Biochemistry 2nd edition Bioinformatics Chemistry for Biologists 2nd edition Developmental Biology Ecology 2nd edition Immunology 2nd edition Genetics 2nd edition Microbiology 2nd edition Molecular Biology 2nd edition Neuroscience Plant Biology Chemistry series Consulting Editor: Howard Stanbury Analytical Chemistry Inorganic Chemistry 2nd edition Medicinal Chemistry Organic Chemistry 2nd edition Physical Chemistry Psychology series Sub-series Editor: Hugh Wagner Dept of Psychology, University of Central Lancashire, Preston, UK Psychology Cognitive Psychology Forthcoming title Physiological Psychology Immunology Second Edition P.M. Lydyard Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, University College London, London, UK A. Whelan Department of Immunology, Trinity College and St James’ Hospital, Dublin, Ireland and M.W. Fanger Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire, USA © Garland Science/BIOS Scientific Publishers Limited, 2004 First published 2000 This edition published in the Taylor & Francis e-Library, 2005. “To purchase your own copy of this or any of Taylor & Francis or Routledge’s collection of thousands of eBooks please go to www.eBookstore.tandf.co.uk.” Second edition published 2004 All rights reserved. No part of this book may be reproduced or
    [Show full text]
  • CD59: a Long-Known Complement Inhibitor Has Advanced to a Blood Group System
    B LOOD G ROUP R EVIEW CD59: A long-known complement inhibitor has advanced to a blood group system C. Weinstock, M. Anliker, and I. von Zabern The blood group system number 35 is based on CD59, a 20-kDa by Zalman et al.1 from the group of H.J. Muller-Eberhard in La membrane glycoprotein present on a large number of different Jolla, California, and in 1988 by Schönermark et al. from the cells, including erythrocytes. The major function of CD59 is to group of G.M. Hänsch in Heidelberg (Germany).2 This inhibitor protect cells from complement attack. CD59 binds to complement components C8 and C9 and prevents the polymerization of C9, was published under the designations “HRF (homologous which is required for the formation of the membrane attack restriction factor)” and “C8bp (C8 binding protein),” complex (MAC). Other functions of CD59 in cellular immunity respectively, to describe its properties.1,2 “C8bp” indicates the are less well defined. CD59 is inserted into the membrane by a glycosylphosphatidylinositol (GPI) anchor. A defect of this anchor binding capacity for C8. The name “HRF” points to a species causes lack of this protein from the cell membrane, which leads to incompatibility of this “factor” that provides protection from an enhanced sensitivity towards complement attack. Patients with complement attack more effectively in a homologous (e.g., paroxysmal nocturnal hemoglobinuria (PNH) harbor a varying human erythrocytes as a target of human complement) than in percentage of red blood cell clones with a defect in GPI-anchored proteins, including CD59. The most characteristic symptoms of a heterologous system (e.g., human erythrocytes as a target of this disease are episodes of hemolysis and thromboses.
    [Show full text]
  • Immunosenescence: a Key Player in Cancer Development Jingyao Lian1,2†, Ying Yue1,2,3†, Weina Yu1,2† and Yi Zhang1,2*
    Lian et al. J Hematol Oncol (2020) 13:151 https://doi.org/10.1186/s13045-020-00986-z REVIEW Open Access Immunosenescence: a key player in cancer development Jingyao Lian1,2†, Ying Yue1,2,3†, Weina Yu1,2† and Yi Zhang1,2* Abstract Immunosenescence is a process of immune dysfunction that occurs with age and includes remodeling of lymphoid organs, leading to changes in the immune function of the elderly, which is closely related to the development of infections, autoimmune diseases, and malignant tumors. T cell–output decline is an important feature of immunose- nescence as well as the production of senescence-associated secretory phenotype, increased glycolysis, and reactive oxygen species. Senescent T cells exhibit abnormal phenotypes, including downregulation of CD27, CD28, and upreg- ulation of CD57, killer cell lectin-like receptor subfamily G, Tim-3, Tight, and cytotoxic T-lymphocyte-associated protein 4, which are tightly related to malignant tumors. The role of immunosenescence in tumors is sophisticated: the many factors involved include cAMP, glucose competition, and oncogenic stress in the tumor microenvironment, which can induce the senescence of T cells, macrophages, natural killer cells, and dendritic cells. Accordingly, these senescent immune cells could also afect tumor progression. In addition, the efect of immunosenescence on the response to immune checkpoint blocking antibody therapy so far is ambiguous due to the low participation of elderly cancer patients in clinical trials. Furthermore, many other senescence-related interventions could be possible with genetic and pharmacological methods, including mTOR inhibition, interleukin-7 recombination, and NAD + activation. Overall, this review aims to highlight the characteristics of immunosenescence and its impact on malignant tumors and immunotherapy, especially the future directions of tumor treatment through senescence-focused strategies.
    [Show full text]
  • Role of Lymphocytic Choriomeningitis Virus (LCMV) in Understanding Viral Immunology: Past, Present and Future
    Viruses 2012, 4, 2650-2669; doi:10.3390/v4112650 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Role of Lymphocytic Choriomeningitis Virus (LCMV) in Understanding Viral Immunology: Past, Present and Future Xin Zhou 1, Srividya Ramachandran 1, Margaret Mann 1 and Daniel L. Popkin 2,* 1 Department of Dermatology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA; E-Mails: [email protected] (X.Z.); [email protected] (S.R.); [email protected] (M.M.) 2 Department of Dermatology, Pathology, Microbiology & Molecular Biology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-216-368-0237; Fax: +1-216-844-8993. Received: 30 September 2012; in revised form: 18 October 2012 / Accepted: 24 October 2012 / Published: 29 October 2012 Abstract: Lymphocytic choriomeningitis virus (LCMV) is a common infection of rodents first identified over eighty years ago in St. Louis, MO, U.S.A. It is best known for its application in immunological studies. The history of LCMV closely correlates with the development of modern immunology. With the use of LCMV as a model pathogen several key concepts have emerged: Major Histocompatibility Complex (MHC) restriction, T cell memory, persistent infections, T cell exhaustion and the key role of immune pathology in disease. Given the phenomenal infrastructure within this field (e.g., defined immunodominant and subdominant epitopes to all T cell receptor specificities as well as the cognate tetramers for enumeration in vivo) the study of LCMV remains an active and productive platform for biological research across the globe to this day.
    [Show full text]
  • Targeting Costimulatory Molecules in Autoimmune Disease
    Targeting costimulatory molecules in autoimmune disease Natalie M. Edner1, Gianluca Carlesso2, James S. Rush3 and Lucy S.K. Walker1 1Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF 2Early Oncology Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, MD, USA 3Autoimmunity, Transplantation and Inflammation Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland *Correspondence: Professor Lucy S.K. Walker. Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF. Tel: +44 (0)20 7794 0500 ext 22468. Email: [email protected]. 1 Abstract Therapeutic targeting of immune checkpoints has garnered significant attention in the area of cancer immunotherapy, and efforts have focused in particular on the CD28 family members CTLA-4 and PD-1. In autoimmunity, these same pathways can be targeted to opposite effect, to curb the over- exuberant immune response. The CTLA-4 checkpoint serves as an exemplar, whereby CTLA-4 activity is blocked by antibodies in cancer immunotherapy and augmented by the provision of soluble CTLA-4 in autoimmunity. Here we review the targeting of costimulatory molecules in autoimmune disease, focusing in particular on the CD28 family and TNFR family members. We present the state-of-the-art in costimulatory blockade approaches, including rational combinations of immune inhibitory agents, and discuss the future opportunities and challenges in this field. 2 The risk of autoimmune disease is an inescapable consequence of the manner in which the adaptive immune system operates. To ensure effective immunity against a diverse array of unknown pathogens, antigen recognition systems based on random gene rearrangement and mutagenesis have evolved to anticipate the antigenic universe.
    [Show full text]
  • Immunology 101
    Immunology 101 Justin Kline, M.D. Assistant Professor of Medicine Section of Hematology/Oncology Committee on Immunology University of Chicago Medicine Disclosures • I served as a consultant on Advisory Boards for Merck and Seattle Genetics. • I will discuss non-FDA-approved therapies for cancer 2 Outline • Innate and adaptive immune systems – brief intro • How immune responses against cancer are generated • Cancer antigens in the era of cancer exome sequencing • Dendritic cells • T cells • Cancer immune evasion • Cancer immunotherapies – brief intro 3 The immune system • Evolved to provide protection against invasive pathogens • Consists of a variety of cells and proteins whose purpose is to generate immune responses against micro-organisms • The immune system is “educated” to attack foreign invaders, but at the same time, leave healthy, self-tissues unharmed • The immune system can sometimes recognize and kill cancer cells • 2 main branches • Innate immune system – Initial responders • Adaptive immune system – Tailored attack 4 The immune system – a division of labor Innate immune system • Initial recognition of non-self (i.e. infection, cancer) • Comprised of cells (granulocytes, monocytes, dendritic cells and NK cells) and proteins (complement) • Recognizes non-self via receptors that “see” microbial structures (cell wall components, DNA, RNA) • Pattern recognition receptors (PRRs) • Necessary for priming adaptive immune responses 5 The immune system – a division of labor Adaptive immune system • Provides nearly unlimited diversity of receptors to protect the host from infection • B cells and T cells • Have unique receptors generated during development • B cells produce antibodies which help fight infection • T cells patrol for infected or cancerous cells • Recognize “foreign” or abnormal proteins on the cell surface • 100,000,000 unique T cells are present in all of us • Retains “memory” against infections and in some cases, cancer.
    [Show full text]
  • Essential Thrombocythemia Facts No
    Essential Thrombocythemia Facts No. 12 in a series providing the latest information for patients, caregivers and healthcare professionals www.LLS.org • Information Specialist: 800.955.4572 Introduction Highlights Essential thrombocythemia (ET) is one of several l Essential thrombocythemia (ET) is one of a related “myeloproliferative neoplasms” (MPNs), a group of closely group of blood cancers known as “myeloproliferative related blood cancers that share several features, notably the neoplasms” (MPNs) in which cells in the bone “clonal” overproduction of one or more blood cell lines. marrow that produce the blood cells develop and All clonal disorders begin with one or more changes function abnormally. (mutations) to the DNA in a single cell; the altered cells in l ET begins with one or more acquired changes the marrow and the blood are the offspring of that one (mutations) to the DNA of a single blood-forming mutant cell. Other MPNs include polycythemia vera and cell. This results in the overproduction of blood cells, myelofibrosis. especially platelets, in the bone marrow. The effects of ET result from uncontrolled blood cell l About half of individuals with ET have a mutation production, notably of platelets. Because the disease arises of the JAK2 (Janus kinase 2) gene. The role that this from a change to an early blood-forming cell that has the mutation plays in the development of the disease, capacity to form red cells, white cells and platelets, any and the potential implications for new treatments, combination of these three cell lines may be affected – and are being investigated. usually each cell line is affected to some degree.
    [Show full text]
  • Biochemical Engineering)
    UNIVERSITY SCHOOL OF CHEMICAL TECHNOLOGY SCHEME OF EXAMINATION B.TECH (BIOCHEMICAL ENGINEERING) Table of Contents FIRST SEMESTER EXAMINATION ......................................................................................................... 4 BA-109 Mathematics I .................................................................................................................................. 5 BA-111 Physics I .......................................................................................................................................... 6 BA-117 Organic Chemistry .......................................................................................................................... 7 HS-101 Communication Skills I ................................................................................................................... 8 BA-119* Impact of Science & Technology on Society ................................................................................ 9 IT-105 Introduction to Computers .............................................................................................................. 10 IT-107 Electrical Science ............................................................................................................................ 11 BA-163 Organic Chemistry Lab ................................................................................................................. 12 BA-153 Physics I Lab ................................................................................................................................
    [Show full text]
  • Quantitative Immunology for Physicists
    bioRxiv preprint doi: https://doi.org/10.1101/696567; this version posted July 28, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Quantitative Immunology for Physicists Gr´egoireAltan-Bonnet,1, ∗ Thierry Mora,2, ∗ and Aleksandra M. Walczak2, ∗ 1Immunodynamics Section, Cancer & Inflammation Program, National Cancer Institute, Bethesda MD 20892, USA 2Laboratoire de physique de l'Ecole´ normale sup´erieure (PSL University), CNRS, Sorbonne Universit´e,Universit´ede Paris, 75005 Paris, France Abstract. The adaptive immune system is a dynamical, self-organized multiscale system that protects vertebrates from both pathogens and internal irregularities, such as tumours. For these reason it fascinates physicists, yet the multitude of different cells, molecules and sub-systems is often also petrifying. Despite this complexity, as experiments on different scales of the adaptive immune system become more quantitative, many physicists have made both theoretical and experimental contributions that help predict the behaviour of ensembles of cells and molecules that participate in an immune response. Here we review some recent contributions with an emphasis on quantitative questions and methodologies. We also provide a more general methods section that presents some of the wide array of theoretical tools used in the field. CONTENTS A. Cytokine signaling and the JAK-STAT pathway 14 I. Introduction 2 1. Cytokine binding and signaling at equilibrium 15 II. Physical chemistry of ligand-receptor 2. Tunability of cytokine responses. 15 interaction: specificity, sensitivity, kinetics. 4 3. Regulation by cytokine consumption 17 A. Diffusion-limited reaction rates 4 4.
    [Show full text]